ArticleJournal of the American Geriatrics Society2025
Prevalence and Duration of Potential Drug-Drug Interactions Among US Nursing Home Residents, 2018-2020.
Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drug-Drug Interaction Signals for Major Bleeding in Nursing Home Residents: High-Throughput Screening of Clopidogrel and Oral Anticoagulants.Pharmacoepidemiology and drug safety · 2026Article
- Prevalence and Duration of Potential Drug-Drug Interactions Among US Nursing Home Residents, 2018-2020.Journal of the American Geriatrics Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNursing home (NH) residents are at increased risk of drug-drug interactions (DDIs) due to multimorbidity and polypharmacy. While prior research suggests that many DDIs lead to adverse drug events in older adults, the extent of exposure to potentially clinically relevant DDIs among United States (US) NH residents is largely unknown.
methodsIn this cohort study, we calculated the prevalence and duration of exposure to 98 potential DDIs among US NH residents from 2018 to 2020. DDIs were sourced from three expert consensus publications, some of which defined similar interactions and overlapping drug combinations, allowing comparisons within and across lists. Data were drawn from Medicare claims linked to Minimum Data Set 3.0 clinical assessments. Eligible residents included Medicare Fee-for-Service beneficiaries aged ≥ 66 years living in NHs with observable Part D prescription drug data. DDI exposure was defined as ≥ 1 day of concurrent use of orally administered medications. Prevalence was calculated as the proportion of residents exposed to each DDI; duration was measured as the median number of days residents concurrently used the medications of interest.
resultsAmong 485,251 NH residents, 61.6% experienced ≥ 1 potential DDI over 272,780 person-years. The 12 most prevalent DDIs involved central nervous system (CNS)-active drugs, anticholinergics, antihypertensives, opioids, and diuretics. Of these DDIs, concurrent use of acetylcholinesterase inhibitors and heart rate-reducing drugs had the longest median exposure duration (81 days; Q1-Q3, 24-235). The most prevalent DDI, concomitant use of ≥ 3 CNS-active drugs, was observed in 27.1% (95% CLs, 27.0%, 27.2%) of residents.
conclusionsNearly two-thirds of NH residents were exposed to medication combinations linked to potential DDIs, although the prevalence and duration of exposure associated with individual DDIs varied. Future research should determine which DDIs are most clinically significant and investigate barriers to reducing exposure duration in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.